July 14, 2008
Invitrogen Acquires ABI
Invitrogen acquired Applied Biosystems in a blockbuster $6.7 billion deal, and will adopt the ABI name. Invitrogen CEO Greg Lucier called 90 percent of deal “an absolutely perfect fit,” especially the acquisition of ABI’s SOLiD next-gen DNA sequencing system. Questions linger, however, over the fate of ABI’s mass spec business, which faces tough competition from Thermo Fisher, Agilent, and Waters.
Helicos Partners with COG
Helicos BioSciences has entered into a scientific collaboration with the Children’s Oncology Group (COG) to study the genomic variety in sarcomas. The collaboration will make use of the Helicos True Single Molecule Sequencing technology to measure the DNA sequence, methylation state, and mRNA expression levels of normal, primary, and metastatic cell states, hopefully tracing the progression of cancer in each patient.
Adverse Event Consortium
The International Serious Adverse Events Consortium (SAEC) has added four organizations to its roster. Novartis, Takeda, and Daiichi Sankyo, all pharma companies, and the Wellcome Trust have joined the non-profit to provide scientific leadership, funding, and possibly “cases” to enhance SAEC research endeavors. SAEC was founded in the fall of 2007 to work with pharma, FDA, and researchers to ID and confirm genetic markers that may predict serious adverse events.
Live Imaging with OMX
The UC Davis Center for Biophotonics Science and Technology has installed the first commercial version of the world’s highest resolution wide-field light microscope. The OMX (optical microscope experimental) allows live cellular processes to be viewed at the smallest possible levels as they occur.
This article appeared in Bio-IT World Magazine.
Subscriptions are free for qualifying individuals. Apply Today.